sahinozgur

Kubra presented a poster entitled “Targeting TACC3 inhibits metastasis in breast cancer with centrosome amplification“. Ozge presented a poster entitled “LINC00152-regulated PDE4D mediates drug resistance and metastasis in highly aggressive breast cancer“.

Baris has been accepted into the Biomedical Sciences Graduate Program at MUSC, wishing him great success in his doctoral journey.

“Hollings team marks milestone in progress toward investigational new drug for triple-negative breast cancer” https://hollingscancercenter.musc.edu/news/archive/2024/07/22/lox-inhibitor-for-triple-negative-breast-cancer

A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer https://www.sciencedirect.com/science/article/pii/S2451945624002733?via%3Dihub

We participated in the AACR conference with three distinct poster presentations.

Ozgur Sahin was recognized for his work and article, “Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer,” published by Nature Communications Nov. 2, 2023. https://medicine.musc.edu/research/excellence-awards

https://hollingscancercenter.musc.edu/news/archive/2024/02/06/hollings-researchers-demonstrate-restoring-effectiveness-of-breast-cancer-drug-after-resistance

We are thrilled to share the news that Ozge, our PhD candidate, has successfully defended her thesis entitled “Targeted Multimodal Approaches to Treat Aggressive Breast Cancers via Therapeutic Inhibition of Key Vulnerabilities.” Her completion of the PhD program is distinguished by a noteworthy contribution of high-impact papers in the field. Read more

We participated in the Drug Discovery and Development Retreat organized by MUSC and USC. During the event, we had the opportunity to engage with numerous presentations on translational cancer research, including Dr. Sahin’s insightful talk on “From mechanism of resistance to drug discovery: Targeting the most aggressive breast cancers.” Members Read more

Our postdoctoral researcher, Metin, has been awarded the prestigious Hollings Postdoctoral Fellowship —a well-deserved recognition of his outstanding work.